CEFTRIAXONE INJECTION, USP SOLUTION

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Kup teraz

Składnik aktywny:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

Dostępny od:

BAXTER CORPORATION

Kod ATC:

J01DD04

INN (International Nazwa):

CEFTRIAXONE

Dawkowanie:

2000MG

Forma farmaceutyczna:

SOLUTION

Skład:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 2000MG

Droga podania:

INTRAVENOUS

Sztuk w opakowaniu:

15G/50G

Typ recepty:

Prescription

Dziedzina terapeutyczna:

THIRD GENERATION CEPHALOSPORINS

Podsumowanie produktu:

Active ingredient group (AIG) number: 0117292012; AHFS:

Status autoryzacji:

APPROVED

Data autoryzacji:

2020-06-02

Charakterystyka produktu

                                PRODUCT MONOGRAPH
Including Patient Medication Information
PR
CEFTRIAXONE INJECTION, USP
CEFTRIAXONE (AS CEFTRIAXONE SODIUM USP)
1000 MG / 50 ML AND 2000 MG / 50 ML IN SINGLE DOSE GALAXY CONTAINERS
READY-TO-USE
STERILE SOLUTION (FROZEN)
ANTIBIOTIC
BAXTER CORPORATION
7125 Mississauga Road
Mississauga, Ontario
L5N 0C2
CONTROL #: 215096
Date of Preparation: May 28, 2020
BAXTER AND GALAXY ARE REGISTERED TRADEMARKS OF BAXTER
INTERNATIONAL INC.
Ceftriaxone Injection, USP
Page 2 of 52
TABLE OF CONTENTS
HEALTH PROFESSIONAL INFORMATION
.........................................................................
3
ACTION
......................................................................................................................................
3
INDICATIONS AND CLINICAL USES
...................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS
...............................................................................................................................
4
PRECAUTIONS
.........................................................................................................................
7
ADVERSE REACTIONS
...........................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
........................................................ 10
DOSAGE AND ADMINISTRATION
.....................................................................................
10
ADMINISTRATION
................................................................................................................
11
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
12
PHARMACEUTICAL INFORMATION
.................................................................................
13
DRUG SUBSTANCE
.................................................................
                                
                                Przeczytaj cały dokument
                                
                            

Dokumenty w innych językach

Charakterystyka produktu Charakterystyka produktu francuski 28-05-2020

Wyszukaj powiadomienia związane z tym produktem